Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Sali RCTsofosbuvirlopinavir/ritonavirCOVID 19 hospitalizedhigh
22/32 inconclusive
    Nojomi
          IRCT20180725040596N2    		 RCTumifenovir (arbidol)lopinavir/ritonavirCOVID 19 hospitalizedsome concern
    		50/50 inconclusive

      COVID-19 mild to moderate meta-analysis

      Babalola RCTivermectinlopinavir/ritonavirCOVID-19 mild to moderatehigh
      		21/20 no results
        Solaymani-Dodaran
                  IRCT20200318046812N1        		 RCTfavipiravir lopinavir/ritonavirCOVID-19 mild to moderatesome concern
        		193/187 inconclusive
          ELACOI (Lopinavir/ritonavir)
                      NCT04252885          		 RCTumifenovir (arbidol)lopinavir/ritonavirCOVID-19 mild to moderatesome concern
          		35/34 inconclusive
          • inconclusive 84 % increase in viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
          • inconclusive 8 % increase in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
          Hung et al.
                      NCT04276688          		 RCTlopinavir/ritonavir, ribavirin and interferon beta-1blopinavir/ritonavirCOVID-19 mild to moderatesome concern
          		86/41 conclusif
          • demonstrated 3.4-fold increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 2.9-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
          2 studies excluded by filtering options (0 RCT / 2 OBS)

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

           

          - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons